Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P07333
UPID:
CSF1R_HUMAN
Alternative names:
CSF-1 receptor; Proto-oncogene c-Fms
Alternative UPACC:
P07333; B5A955; D3DQG2; Q6LDW5; Q6LDY4; Q86VW7
Background:
The Macrophage colony-stimulating factor 1 receptor (CSF-1R), also known as Proto-oncogene c-Fms, plays a pivotal role in the regulation of survival, proliferation, and differentiation of hematopoietic precursor cells. It is crucial for normal bone and tooth development, fertility, and immune responses, acting through pathways like ERK1/2, JNK, and AKT1.
Therapeutic significance:
CSF-1R's involvement in diseases such as Leukoencephalopathy, hereditary diffuse, with spheroids 1, and Brain abnormalities, neurodegeneration, and dysosteosclerosis, underscores its potential as a target for therapeutic intervention in neurodegenerative disorders and bone diseases.